Anorectic drugs and vascular disease: The role of voltage-gated K+ channels

Vascular Pharmacology

Volumn 38, Issue 1, 2002, Pages 51-59

  Michelakis, Evangelos ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Anorexigens; Appetite; Dexfenfluramine; KV channels; Pulmonary hypertension; Sibutramine; Vascular tone

Indexed keywords

AMINOREX; ANOREXIGENIC AGENT; CALCIUM; CATECHOLAMINE; DEXFENFLURAMINE; FENFLURAMINE; FLUOXETINE; MARKER; NITRIC OXIDE SYNTHASE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; SEROTONIN; SIBUTRAMINE; VOLTAGE GATED POTASSIUM CHANNEL;

APPETITE; ARTICLE; BLOOD REGURGITATION; CALCIUM CELL LEVEL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL FUNCTION; DIGITAL ARTERY; DISEASE COURSE; DRUG EFFECT; DRUG USE; ENDOTHELIUM CELL; EPIDEMIC; HEART VALVE; HUMAN; HYPERTENSION; ISCHEMIA; LONG QT SYNDROME; LUNG CIRCULATION; MESENTERIC ARTERY; MOLECULE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SEROTONIN BRAIN LEVEL; STROKE; SYSTEMIC CIRCULATION; THROMBOCYTE; THROMBOSIS; VALVULAR HEART DISEASE; VASCULAR DISEASE; VASOCONSTRICTION;

ANIMALS; APPETITE DEPRESSANTS; CALCIUM; CARDIOVASCULAR DISEASES; HUMANS; OBESITY; POTASSIUM CHANNELS, VOLTAGE-GATED; VASOCONSTRICTION;

EID: 0036461636     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1537-1891(02)00126-X     Document Type: Article

References (58)

1. Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., Higenbottam T., Oakley C., Wouters E., Aubier M., Simoneau G., Begaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N. Engl. J. Med. 335:1996;609-616.
2. Ackerman M.J., Clapham D.E. Mechanisms of disease: ion channels - basic science and clinical disease. N. Engl. J. Med. 336:1997;1575-1586.
3. Archer S., Rich S. Primary pulmonary hypertension: a vascular biology and translational research "Work in progress" Circulation. 102:2000;2781-2791.
4. Archer S., Djaballah K., Humbert M., Weir E., Fartoukh M., Simonneau G., Dihn-Xuan A. Nitric oxide deficiency in pulmonary hypertension associated with use of the anorectic agents fenfluramine and dexfenfluramine. Am. J. Respir. Crit. Care Med. 158:1998;1061-1067.
5. Archer S., Souil E., Dinh-Xuan A., Schremmer B., Mercier J., Al Yaagoubi A., Nguyen-Hu L., Reeve H., Hampl V. Molecular identification of the role of voltage-gated K channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J. Clin. Invest. 101:1998;2319-2330.
6. 2-sensitive potassium channels in the pulmonary circulation. Adv. Exp. Med. Biol. 475:2000;219-240.
7. Atanassoff P., Weiss B.M., Schnid E., Tornic M. Pulmonary hypertension and dexfenfluramine. Lancet. 339:1992;436.
8. Brenot F., Herve P., Petitpretz P., Parent F., Duroux P., Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br. Heart J. 70:1993;537-541.
9. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwards B.S., Edwards W.D., Schaff H.V. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337:1997;581-588.
10. Douglas J., Munro A., Kitchin H., Muir A., Proudfoot A. Pulmonary hypertension and fenfluramine. Br. Med. J. 283:1981;881-883.
11. Eddahibi S., Raffestin B., Launay J.M., Sitbon M., Adnot S. Effect of dexfenfluramine treatment in rats exposed to acute and chronic hypoxia. Am. J. Respir. Crit. Care Med. 157:1998;1111-1119.
12. Evrad P., Allaz A.F., Urban P. Myocardial infarction associated with the use of dexfenfluramine. Br. Med. J. 301:1990;345.
13. Fishman A.P., Pietra G.G. Handling of bioactive materials by the lung. N. Engl. J. Med. 291:1974;953-959.
14. Glazer G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch. Intern. Med. 161:2001;1814-1824.
15. Griendling K.K., Sorescu D., Lassegue B., Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler. Thromb. Vasc. Biol. 20:2000;2175-2183.
16. Herve P., Launay J., Scrobonaci M., Brenot F., Simonneau G., Petitpretz P., Poubeau P., Cerrina J., Duroux P., Drouet L. Increased plasma serotonin in primary pulmonary hypertension. Am. J. Med. 99:1995;249-254.
17. Higenbottam T., Marriott H., Cremona G., Laude E., Bee D. The acute effects of dexfenfluramine on human and porcine pulmonary vascular tone and resistance. Chest. 116:1999;921-930.
18. Hranilovic D., Lesch K.P., Ugarkovic D., Cicin-Sain L., Jernej B. Identification of serotonin transporter mRNA in rat platelets. J. Neural Transm. 103:1996;957-965.
19. Kay J., Smith P., Heath D. Aminorex and the pulmonary circulation. Thorax. 26:1971;262-270.
20. Lee S.L., Wang W.W., Fanburg B.L. Dexfenfluramine as a mitogen signal via the formation of superoxide anion. FASEB J. 15:2001;1324-1325.
21. + channel current in rat small coronary arteries. Circ. Res. 89:2001;146-152.
22. + channel current in vascular smooth muscle cells from rat mesenteric arteries. J. Membr. Biol. 180:2001;163-175.
23. Mabadeje A.F. Fenfluramine-induced hypertension. West Afr. J. Pharmacol. Drug Res. 2:1974;54P.
24. Mahaut-Smith M., Rink T., Collins S., Sage S. Voltage-gated potassium channels and the control of membrane potential in human platelets. J. Physiol. 428:1990;723-735.
25. Marinella M., Berrettoni B. Digital necrosis associated with dexfenfluramine. N. Engl. J. Med. 337:1997;1776-1777.
26. + channels in genetic and nongenetic hypertension. Circ. Res. 79:1996;295-301.
27. Martens J., Gelband C. Ion channels in vascular smooth muscle: alterations in essential hypertension. Proc. Soc. Exp. Biol. Med. 218:1998;192-203.
28. McMahon F.G., Fujioka K., Singh B.N., Mendel C.M., Rowe E., Rolston K., Johnson F., Mooradian A.D. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch. Intern. Med. 160:2000;2185-2191.
29. McMurray J., Bloomfield P., Miller H. Irreversible pulmonary hypertension after treatment with fenfluramine. Br. Med. J. 292:1986;239-240.
30. McNeely W., Goa K. Sibutramine. A review of its contribution to the management of obesity. Drugs. 56:1998;1093-1124.
31. Michelakis E.D., Weir E.K. Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am. J. Med. Sci. 321:2001;292-299.
32. Michelakis E.D., Weir E.K. The pathobiology of pulmonary hypertension. Smooth muscle cells and ion channels. Clin. Chest Med. 22:2001;419-432.
33. Michelakis E., Johnson G., Leis L., Archer S., Weir E. Dexfenfluramine and 4-aminopyridine (an inhibitor of voltage-gated potassium channels) increase serotonin release from human platelets. Am. J. Resp. Crit. Care Med. 157:1998;A588.
34. Michelakis E.D., Weir E.K., Nelson D.P., Reeve H.L., Tolarova S., Archer S.L. Dexfenfluramine elevates systemic blood pressure by inhibiting potassium currents in vascular smooth muscle cells. J. Pharmacol. Exp. Ther. 291:1999;1143-1149.
35. Miyamoto J.K., Uezu E., Yusa T., Terashima S. Efflux of 5-HIAA from 5-HT neurons: a membrane potential dependent process. Physiol. Behav. 47:1990;767-772.
36. Mlczoch J. Drug and dietary induced pulmonary hypertension. Weir K., Reeves J.T. Pulmonary Hypertension. 1984;341-359 Futura Publishing, Mount Kisco, NY.
37. Naeije R., Maggiorini M., Delcroix M., Leeman M., Melot C. Effects of chronic dexfenfluramine treatment on pulmonary hemodynamics in dogs. Am. J. Respir. Crit. Care Med. 154:1996;1347-1350.
38. Nelson M., Quayle J. Physiological roles and properties of potassium channels in arterial smooth muscle cells. Am. J. Physiol. 37:1995;C799-C822.
39. Patel A., Lazdunski M., Honore E. Kv2.1/Kv9.3, a novel ATP-dependent delayed-rectifier K channel in oxygen-sensitive pulmonary artery myocytes. EMBO J. 16:1997;6615-6625.
40. Pei Q., Leslie R.A., Grahame-Smith D.G., Zetterstrom T.S. 5-HT efflux from rat hippocampus in vivo produced by 4-aminopyridine is increased by chronic lithium administration. NeuroReport. 6:1995;716-720.
41. + channel hKv1.5. J. Pharmacol. Exp. Ther. 298:2001;1108-1119.
42. Platoshyn O., Golovina V.A., Bailey C.L., Limsuwan A., Krick S., Juhaszova M., Seiden J.E., Rubin L.J., Yuan J.X. Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. Am. J. Physiol. 279:2000;C1540-C1549.
43. V channel expression and function in pulmonary artery myocytes. Am. J. Physiol. 280:2001;L801-L812.
44. Pouwels H., Smeets J., Cheriex E., Cheriex E.W. Pulmonary hypertension and fenfluramine. Eur. Respir. J. 3:1990;606-607.
45. Reeve H.L., Archer S.L., Soper M., Weir E. Dexfenfluramine increases pulmonary artery smooth muscle intracellular calcium, independent of membrane potential. Am. J. Physiol. 277:1999;L662-L666.
46. Reeve H.L., Nelson D., Archer S., Weir E. Effects of fluoxetine, phentermine and venlafaxine on pulmonary arterial pressure and electrophysiology. Am. J. Physiol. 276:1999;L213-L219.
47. Reeve H.L., Michelakis E., Nelson D.P., Weir E.K., Archer S.L. Alterations in a redox oxygen sensing mechanism in chronic hypoxia. J. Appl. Physiol. 90:2001;2249-2256.
48. Schembre D., Boynton K. Appetite-suppressant drugs and primary pulmonary hypertension. N. Engl. J. Med. 336:1997;510-511.
49. Schwitter J., Agosti R., Ott P., Kalman A., Waespe W. Small infarctions of cochlear, retinal and encephalic tissue in young women. Stroke. 23:1992;903-907.
50. Thomson J.R., Machado R.D., Pauciulo M.W., Morgan N.V., Humbert M., Elliott G.C., Ward K., Yacoub M., Mikhail G., Rogers P., Newman J., Wheeler L., Higenbottam T., Gibbs J.S., Egan J., Crozier A., Peacock A., Allcock R., Corris P., Loyd J.E., Trembath R.C., Nichols W.C. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J. Med. Genet. 37:2000;741-745.
51. VanItallie T.B. Prevalence of obesity. Endocrinol. Metab. Clin. North Am. 25:1996;887-905.
52. Viskin S. Long QT syndromes and torsade de pointes. Lancet. 354:1999;1625-1633.
53. Weir E.K., Reeve H.L., Huang J., Michelakis E., Nelson D.P., Hampl V., Archer S.L. Anorexic agents aminorex, fenfluramine and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation. 94:1996;2216-2220.
54. Weir E., Reeve H., Johnson G., Michelakis E., Nelson D., Archer S. A role for potassium channels in smooth muscle cells and platelets in the etiology of primary pulmonary hypertension. Chest. 114(3 Suppl):1998;200S-204S.
55. Wirth A., Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA, J. Am. Med. Assoc. 286:2001;1331-1339.
56. + channel genes in mesenteric artery smooth muscle cells. Am. J. Physiol. 277:1999;G1055-G1063.
57. Yuan X., Aldinger A., Juhaszova M., Wang J., Conte J., Gaine S., Orens J., Rubin L. Dysfunctional voltage-gated potassium channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation. 98:1998;1400-1406.
58. + channel gene transcription in primary pulmonary hypertension. Lancet. 351:1998;726-727.